Benign prostatic hyperplasia and subsequent risk of bladder cancer

British Journal of Cancer

Volumn 96, Issue 9, 2007, Pages 1475-1479

  Kang, D ^a,b   Chokkalingam, A P ^c   Gridley, G ^a   Nyren, O ^d   Johansson, J E ^e   Adami, H O ^d   Silverman, D ^a   Hsing, A W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Seoul National University   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Benign prostatic hyperplasia; Population based; Prostate cancer; Standardised incidence ratio

Indexed keywords

ADULT; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CLINICAL OBSERVATION; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FOLLOW UP; GENERAL PRACTITIONER; HOSPITALIZATION; HUMAN; IMMIGRANT; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RISK ASSESSMENT; STANDARDIZATION; SWEDEN; TRANSURETHRAL RESECTION; UROLOGY;

COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; PROSTATIC HYPERPLASIA; REGISTRIES; RISK FACTORS; SWEDEN; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 34247593081     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603730     Document Type: Article

References (13)

1. Bailar JC, Ederer F (1964) Significance factors for ratio of a Poisson variable to its expectation. Biometrics 20: 639-643
2. Blomqvist P, Ekbom A, Carlsson P, Ahlstrand C, Johansson JE (1997) Benign prostatic hyperplasia in Sweden 1987 to 1994: changing patterns of treatment, changing patterns of costs. Urology 50: 214-219, discussion 219-220
3. Borth CS, Beiko DT, Nickel JC (2001) Impact of medical therapy on transurethral resection of the prostate: a decade of change. Urology 57: 1082-1085, discussion 1085-1086
4. Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II - The design and analysis of cohort studies. IARC Sci Publ 82: 1-406
5. Chokkalingam AP, Nyren O, Johansson JE, Gridley G, McLaughlin JK, Adami HO, Hsing AW (2003) Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. Cancer 98: 1727-1734
6. Chow WH, Lindblad P, Gridley G, Nyren O, McLaughlin JK, Linet MS, Pennello GA, Adami HO, Fraumeni Jr JF (1997) Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst 89: 1453-1457
7. Djavan B, Nickel JC, de la Rosette J, Abrams P (2002) The urologist view of BPH progression: results of an international survey. Eur Urol 41: 490-496
8. Faul P (1993) Video TUR: raising the gold standard. New aspects, techniques and tendencies to minimize invasiveness. Eur Urol 24: 256-261
9. Graves EJ, Kozak LJ (1998) Detailed diagnoses and procedures, National Hospital Discharge Survey, 1996. Vital Health Stat 13 i-iii: 1-151
10. Jacobsen SJ, Girman CJ, Lieber MM (2001) Natural history of benign prostatic hyperplasia. Urology 58: 5-16, discussion 16
11. Kadlubar FF, Dooley KL, Teitel CH, Roberts DW, Benson RW, Butler MA, Bailey JR, Young JF, Skipper PW, Tannenbaum SR (1991) Frequency of urination and its effects on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in beagle dogs given the carcinogen 4-aminobiphenyl. Cancer Res 51: 4371-4377
12. Lubin JH, Gail MH (1984) Biased selection of controls for case-control analyses of cohort studies. Biometrics 40: 63-75
13. Mattsson B, Wallgren A (1984) Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 23: 305-313